Index RUT
P/E -
EPS (ttm) -0.51
Insider Own 19.16%
Shs Outstand 116.86M
Perf Week -4.07%
Market Cap 524.74M
Forward P/E -
EPS next Y -0.38
Insider Trans 2.25%
Shs Float 94.69M
Perf Month -16.88%
Income -50.62M
PEG -
EPS next Q -0.16
Inst Own 59.22%
Short Float 5.81%
Perf Quarter -27.63%
Sales 34.16M
P/S 15.36
EPS this Y -14.95%
Inst Trans 0.72%
Short Ratio 11.35
Perf Half Y -1.10%
Book/sh 2.69
P/B 1.66
EPS next Y 35.67%
ROA -12.03%
Short Interest 5.51M
Perf Year 28.00%
Cash/sh 0.74
P/C 6.03
EPS next 5Y -
ROE -15.43%
52W Range 3.14 - 6.72
Perf YTD -27.39%
Dividend Est. -
P/FCF 749.63
EPS past 5Y -
ROI -15.04%
52W High -33.28%
Beta -0.05
Dividend TTM -
Quick Ratio 4.11
Sales past 5Y 13.92%
Gross Margin 44.37%
52W Low 42.68%
ATR (14) 0.19
Dividend Ex-Date -
Current Ratio 4.11
EPS Y/Y TTM -121.77%
Oper. Margin -202.63%
RSI (14) 30.00
Volatility 2.76% 3.22%
Employees 106
Debt/Eq 0.08
Sales Y/Y TTM -3.34%
Profit Margin -148.16%
Recom 1.00
Target Price 10.00
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q -292.72%
Payout -
Rel Volume 1.23
Prev Close 4.43
Sales Surprise -35.38%
EPS Surprise 1.75%
Sales Q/Q -86.36%
Earnings May 09 AMC
Avg Volume 485.11K
Price 4.48
SMA20 -10.81%
SMA50 -15.79%
SMA200 -15.80%
Trades
Volume 598,741
Change 1.13%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-29-23 Initiated
RBC Capital Mkts
Outperform
$6
Apr-21-23 Initiated
The Benchmark Company
Buy
$8
Apr-13-23 Initiated
Craig Hallum
Buy
$10
Feb-22-23 Initiated
Cowen
Outperform
$10
Feb-13-23 Initiated
H.C. Wainwright
Buy
$11
Dec-20-22 Initiated
Truist
Buy
$10
Dec-16-22 Initiated
Credit Suisse
Outperform
$13
Nov-29-22 Initiated
SVB Leerink
Outperform
$6
Nov-28-22 Initiated
Stifel
Buy
$12
Apr-22-24 08:00AM
Mar-21-24 11:31AM
Mar-20-24 08:54PM
04:05PM
Feb-28-24 08:27AM
08:00AM
Loading…
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Dec-14-23 04:30PM
Nov-20-23 12:39PM
Nov-14-23 05:03AM
Nov-09-23 05:55PM
09:24AM
08:00AM
Nov-02-23 08:00AM
Nov-01-23 09:00AM
04:28PM
Loading…
Oct-31-23 04:28PM
Oct-26-23 02:32PM
Oct-12-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:20AM
Aug-13-23 08:06AM
Aug-10-23 04:05PM
Aug-07-23 04:05PM
Jul-31-23 08:00AM
Jul-17-23 07:35AM
Jun-13-23 06:00AM
May-18-23 05:09PM
May-17-23 04:05PM
May-16-23 06:06AM
May-14-23 08:03AM
10:55PM
Loading…
May-11-23 10:55PM
(Thomson Reuters StreetEvents)
07:00AM
May-05-23 07:14AM
May-04-23 06:26AM
May-01-23 08:00AM
Apr-26-23 08:01PM
Apr-25-23 08:00AM
Apr-19-23 08:30AM
Apr-07-23 10:24PM
Apr-05-23 06:09AM
Apr-02-23 08:51AM
Mar-31-23 08:40AM
Mar-30-23 04:05PM
Mar-15-23 11:44AM
Mar-09-23 08:00AM
Mar-08-23 09:53AM
Feb-23-23 07:49AM
Feb-07-23 08:00AM
Feb-01-23 06:56AM
Dec-16-22 12:39PM
Dec-01-22 08:47AM
Nov-15-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 07:00AM
Nov-01-22 04:01PM
04:01PM
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GUSTAFSON KURT A Executive VP, Finance and CFO Apr 08 '24 Sale 5.27 6,954 36,648 176,697 Apr 09 06:38 PM Berkman Charles S Chief Legal Officer Apr 08 '24 Sale 5.27 6,954 36,648 292,617 Apr 09 06:37 PM GUSTAFSON KURT A Executive VP, Finance & CFO Apr 01 '24 Sale 5.46 11,849 64,696 170,110 Apr 02 06:30 PM FOEHR MATTHEW W President and CEO Mar 27 '24 Option Exercise 3.72 243,613 907,023 3,152,416 Mar 29 04:52 PM FOEHR MATTHEW W President and CEO Mar 22 '24 Buy 5.19 225,000 1,167,750 2,908,803 Mar 25 07:07 AM FOEHR MATTHEW W Chief Executive Officer Dec 12 '23 Buy 5.05 200,000 1,010,000 2,645,442 Dec 13 03:25 PM FOEHR MATTHEW W President and CEO Nov 10 '23 Buy 4.27 95,000 405,517 2,427,919 Nov 13 08:00 AM FOEHR MATTHEW W President and CEO Aug 14 '23 Buy 5.48 45,000 246,600 2,332,919 Aug 15 04:56 PM FOEHR MATTHEW W Chief Executive Officer Jun 09 '23 Buy 4.52 115,000 519,800 2,574,009 Jun 12 04:47 PM HIGGINS JOHN L Director May 23 '23 Option Exercise 3.68 9,000 33,120 2,471,686 May 25 04:45 PM HIGGINS JOHN L Director May 23 '23 Sale 4.05 9,000 36,450 2,462,686 May 25 04:45 PM HIGGINS JOHN L Director May 19 '23 Option Exercise 3.68 1,000 3,680 2,463,686 May 23 04:12 PM HIGGINS JOHN L Director May 19 '23 Sale 4.05 1,000 4,050 2,462,686 May 23 04:12 PM HIGGINS JOHN L Director May 18 '23 Option Exercise 3.68 50,000 184,000 2,512,686 May 19 05:03 PM HIGGINS JOHN L Director May 18 '23 Sale 3.89 50,000 194,500 2,462,686 May 19 05:03 PM FOEHR MATTHEW W Chief Executive Officer May 12 '23 Buy 3.40 440,000 1,496,000 2,438,414 May 15 04:02 PM
Index RUT
P/E 24.33
EPS (ttm) 2.90
Insider Own 6.22%
Shs Outstand 17.56M
Perf Week -2.62%
Market Cap 1.25B
Forward P/E 12.59
EPS next Y 5.60
Insider Trans -0.18%
Shs Float 16.60M
Perf Month -0.98%
Income 52.15M
PEG 1.22
EPS next Q 0.83
Inst Own 92.70%
Short Float 4.98%
Perf Quarter -7.69%
Sales 131.31M
P/S 9.52
EPS this Y -27.09%
Inst Trans -0.32%
Short Ratio 4.77
Perf Half Y 40.33%
Book/sh 39.92
P/B 1.77
EPS next Y 26.20%
ROA 6.94%
Short Interest 0.83M
Perf Year -9.02%
Cash/sh 9.62
P/C 7.34
EPS next 5Y 20.00%
ROE 8.29%
52W Range 49.24 - 94.57
Perf YTD -1.19%
Dividend Est. -
P/FCF 27.71
EPS past 5Y -13.18%
ROI 7.38%
52W High -25.38%
Beta 1.04
Dividend TTM -
Quick Ratio 12.72
Sales past 5Y -3.89%
Gross Margin 67.06%
52W Low 43.32%
ATR (14) 2.63
Dividend Ex-Date Jul 02, 2010
Current Ratio 14.15
EPS Y/Y TTM 253.69%
Oper. Margin 7.48%
RSI (14) 39.95
Volatility 3.77% 3.23%
Employees 58
Debt/Eq 0.01
Sales Y/Y TTM -40.20%
Profit Margin 39.72%
Recom 1.20
Target Price 116.80
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q 199.40%
Payout 0.00%
Rel Volume 0.51
Prev Close 70.37
Sales Surprise 9.58%
EPS Surprise 108.87%
Sales Q/Q -44.22%
Earnings May 07 AMC
Avg Volume 173.25K
Price 70.57
SMA20 -7.06%
SMA50 -5.69%
SMA200 5.45%
Trades
Volume 88,152
Change 0.28%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-14-21 Resumed
Stephens
Overweight
$200
Feb-04-21 Reiterated
H.C. Wainwright
Buy
$229 → $310
Oct-06-20 Initiated
Barclays
Overweight
$156
Mar-24-20 Downgrade
Argus
Buy → Hold
Mar-10-20 Initiated
Guggenheim
Neutral
Feb-06-20 Initiated
The Benchmark Company
Buy
$135
Sep-19-19 Upgrade
Barclays
Equal Weight → Overweight
$110 → $132
Jun-11-19 Initiated
Barclays
Equal Weight
$131
May-03-19 Reiterated
H.C. Wainwright
Buy
$254 → $214
Mar-06-19 Reiterated
H.C. Wainwright
Buy
$281 → $254
Oct-29-18 Upgrade
ROTH Capital
Neutral → Buy
Oct-02-18 Reiterated
H.C. Wainwright
Buy
$270 → $280
Sep-11-18 Reiterated
Argus
Buy
$260 → $300
Aug-17-18 Initiated
Goldman
Neutral
$256
Aug-08-18 Downgrade
ROTH Capital
Buy → Neutral
Jun-21-18 Initiated
Argus
Buy
$260
Dec-27-17 Reiterated
H.C. Wainwright
Buy
$163 → $169
Sep-05-17 Resumed
H.C. Wainwright
Buy
$150
Oct-05-16 Reiterated
H.C. Wainwright
Buy
$146 → $160
Aug-05-16 Downgrade
Deutsche Bank
Hold → Sell
$104 → $110
Show Previous Ratings
Apr-23-24 08:31AM
Apr-17-24 09:55AM
Apr-08-24 08:15AM
Apr-05-24 06:00PM
Apr-04-24 09:30AM
09:00AM
Loading…
09:00AM
Apr-03-24 09:00AM
Apr-01-24 06:15PM
Mar-28-24 11:30AM
Mar-26-24 06:15PM
Mar-21-24 09:00AM
Mar-20-24 06:00PM
Mar-19-24 09:30AM
Mar-14-24 06:00PM
Mar-07-24 09:00AM
04:01PM
Loading…
Mar-05-24 04:01PM
Mar-04-24 08:00AM
Feb-29-24 09:30AM
Feb-28-24 07:34AM
Feb-27-24 07:00AM
Feb-22-24 04:01PM
Feb-16-24 08:00AM
Feb-13-24 04:01PM
Feb-01-24 05:00PM
Jan-10-24 07:30PM
Jan-05-24 04:30PM
Dec-12-23 12:01PM
09:00AM
09:00AM
Dec-11-23 09:00AM
04:02PM
Loading…
Dec-06-23 04:02PM
Dec-01-23 08:20AM
Nov-28-23 09:01AM
Nov-09-23 04:47PM
Nov-08-23 04:01PM
Nov-06-23 09:00AM
Nov-01-23 08:00AM
Oct-25-23 04:01PM
Oct-18-23 08:00AM
Oct-09-23 06:15PM
Oct-03-23 06:00PM
Oct-02-23 09:00AM
09:00AM
Sep-27-23 09:00AM
Sep-26-23 05:05PM
Sep-22-23 09:00AM
Sep-21-23 09:20AM
Sep-18-23 05:17PM
Sep-01-23 10:02PM
Aug-08-23 04:01PM
Jul-27-23 01:30PM
Jul-25-23 04:30PM
Jul-17-23 08:59AM
08:45AM
Jun-29-23 09:00AM
Jun-21-23 08:00PM
Jun-09-23 09:40AM
Jun-06-23 11:40AM
11:10AM
Jun-05-23 11:49AM
09:01AM
Jun-02-23 12:39PM
12:35PM
Jun-01-23 11:29AM
May-30-23 07:01PM
May-25-23 05:00PM
May-24-23 09:55AM
09:40AM
May-17-23 01:59PM
08:07AM
May-16-23 09:56AM
07:30AM
07:00AM
May-12-23 12:08PM
11:34AM
May-11-23 12:25PM
May-08-23 12:32PM
09:55AM
May-06-23 10:13AM
May-05-23 10:00AM
May-04-23 05:45PM
04:01PM
06:26AM
May-02-23 08:30PM
12:06PM
11:40AM
Apr-28-23 02:04PM
Apr-27-23 09:04AM
Apr-26-23 08:00PM
Apr-24-23 04:01PM
Apr-20-23 09:55AM
Apr-19-23 08:30AM
Apr-18-23 12:56PM
Apr-17-23 01:13PM
09:40AM
Apr-14-23 01:48PM
Apr-13-23 06:28AM
Apr-07-23 06:40PM
Apr-06-23 10:23AM
Apr-04-23 12:02PM
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
KOZARICH JOHN W Director Apr 24 '24 Option Exercise 39.35 2,893 113,840 42,523 Apr 26 06:35 PM Davis Todd C Chief Executive Officer Mar 25 '24 Option Exercise 57.39 16,015 919,147 120,160 Mar 27 05:47 PM Aryeh Jason Director Mar 05 '24 Option Exercise 39.35 2,893 113,840 74,422 Mar 06 05:28 PM Sabba Stephen L Director Mar 05 '24 Option Exercise 0.00 2,893 0 30,819 Mar 07 01:27 PM Sabba Stephen L Director Mar 05 '24 Sale 74.30 1,893 140,650 28,926 Mar 07 01:27 PM Espinoza Octavio Chief Financial Officer Feb 28 '24 Option Exercise 56.62 1,264 71,564 29,895 Feb 29 06:50 PM Espinoza Octavio Chief Financial Officer Feb 28 '24 Sale 88.46 140 12,384 29,755 Feb 29 06:50 PM Davis Todd C CHIEF EXECUTIVE OFFICER Sep 22 '23 Buy 59.38 4,000 237,529 73,090 Sep 25 04:44 PM KOZARICH JOHN W Director May 16 '23 Sale 77.20 4,444 343,081 38,488 May 18 05:18 PM Sabba Stephen L Director May 10 '23 Option Exercise 0.00 6,408 0 32,192 May 12 03:43 PM Sabba Stephen L Director May 10 '23 Sale 77.13 6,408 494,225 25,784 May 12 03:43 PM KOZARICH JOHN W Director May 08 '23 Option Exercise 18.82 6,408 120,599 48,621 May 10 07:15 PM KOZARICH JOHN W Director May 08 '23 Sale 76.56 6,408 490,628 42,213 May 10 07:15 PM
Index S&P 500
P/E 46.19
EPS (ttm) 1.39
Insider Own 1.03%
Shs Outstand 157.64M
Perf Week 3.12%
Market Cap 10.07B
Forward P/E 31.61
EPS next Y 2.03
Insider Trans -0.64%
Shs Float 155.57M
Perf Month -7.72%
Income 224.12M
PEG 8.31
EPS next Q 0.45
Inst Own 100.51%
Short Float 3.70%
Perf Quarter -11.80%
Sales 1.15B
P/S 8.79
EPS this Y -11.95%
Inst Trans 1.98%
Short Ratio 5.25
Perf Half Y 4.54%
Book/sh 12.50
P/B 5.13
EPS next Y 15.67%
ROA 8.80%
Short Interest 5.75M
Perf Year -18.30%
Cash/sh 0.86
P/C 74.23
EPS next 5Y 5.56%
ROE 11.82%
52W Range 51.79 - 89.91
Perf YTD -16.98%
Dividend Est. 0.25 (0.40%)
P/FCF 44.68
EPS past 5Y 16.30%
ROI 8.94%
52W High -28.75%
Beta 1.23
Dividend TTM 0.32 (0.50%)
Quick Ratio 3.03
Sales past 5Y 12.42%
Gross Margin 67.23%
52W Low 23.69%
ATR (14) 1.89
Dividend Ex-Date Feb 09, 2024
Current Ratio 4.37
EPS Y/Y TTM -14.72%
Oper. Margin 22.66%
RSI (14) 40.84
Volatility 2.38% 2.63%
Employees 3050
Debt/Eq 0.28
Sales Y/Y TTM 2.25%
Profit Margin 19.57%
Recom 1.43
Target Price 80.40
Option/Short Yes / Yes
LT Debt/Eq 0.28
EPS Q/Q -44.48%
Payout 18.16%
Rel Volume 0.89
Prev Close 62.66
Sales Surprise -1.78%
EPS Surprise -2.96%
Sales Q/Q 0.37%
Earnings May 01 BMO
Avg Volume 1.10M
Price 64.06
SMA20 -3.25%
SMA50 -8.43%
SMA200 -10.12%
Trades
Volume 972,387
Change 2.23%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-08-24 Initiated
Scotiabank
Sector Outperform
$80
Feb-02-24 Downgrade
Stifel
Buy → Hold
$65
Dec-07-23 Initiated
UBS
Buy
$80
Aug-28-23 Initiated
William Blair
Outperform
Jan-10-23 Upgrade
Wells Fargo
Underweight → Equal Weight
$90
Dec-14-22 Initiated
Deutsche Bank
Buy
$100
Dec-12-22 Upgrade
Citigroup
Neutral → Buy
$81.25 → $100
Dec-07-22 Initiated
RBC Capital Mkts
Sector Perform
$89
Aug-25-22 Initiated
Credit Suisse
Outperform
$465
Apr-25-22 Downgrade
Wells Fargo
Equal Weight → Underweight
$370
Sep-15-21 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
$600
Mar-08-21 Upgrade
Stephens
Equal-Weight → Overweight
$380 → $425
Feb-23-21 Upgrade
Stifel
Hold → Buy
$435
Jan-25-21 Reiterated
The Benchmark Company
Buy
$320 → $410
Nov-10-20 Initiated
KeyBanc Capital Markets
Sector Weight
$340
Sep-30-20 Initiated
Atlantic Equities
Overweight
$365
Jul-15-20 Downgrade
Stephens
Overweight → Equal-Weight
May-27-20 Downgrade
Stifel
Buy → Hold
$245 → $260
May-14-20 Initiated
The Benchmark Company
Buy
$290
Jan-08-20 Resumed
Stephens
Overweight
$250
Show Previous Ratings
Apr-26-24 07:00AM
Apr-24-24 10:01AM
Apr-23-24 07:00AM
Apr-10-24 07:00AM
Apr-08-24 07:00AM
07:00AM
Loading…
Apr-03-24 07:00AM
Apr-01-24 07:00AM
Mar-28-24 09:00AM
08:39AM
Mar-22-24 07:00AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-12-24 07:00AM
Mar-11-24 07:00PM
Mar-06-24 07:00AM
06:15AM
Loading…
Feb-23-24 06:15AM
Feb-13-24 08:00AM
Feb-02-24 10:47AM
04:45AM
(Thomson Reuters StreetEvents)
Feb-01-24 12:57PM
07:51AM
07:07AM
06:30AM
06:30AM
Jan-29-24 07:00AM
Jan-25-24 07:00AM
Jan-24-24 07:00AM
Jan-21-24 01:16PM
Jan-16-24 07:00AM
Jan-05-24 07:00AM
07:00AM
Loading…
Jan-04-24 07:00AM
Dec-21-23 07:00AM
Dec-20-23 07:00AM
Dec-14-23 07:00AM
Dec-01-23 01:32AM
Nov-27-23 07:00AM
Nov-13-23 07:00AM
Nov-02-23 07:00AM
Nov-01-23 10:44AM
Oct-31-23 07:53AM
07:27AM
06:30AM
06:30AM
Oct-25-23 03:42PM
09:00AM
Oct-22-23 10:30AM
Oct-20-23 05:01AM
Oct-19-23 07:00AM
Oct-16-23 07:00AM
Oct-10-23 07:00AM
Oct-03-23 09:45AM
Sep-28-23 06:00AM
Sep-27-23 07:00AM
Sep-26-23 07:00AM
Sep-25-23 07:00AM
Sep-23-23 09:00AM
Sep-19-23 02:00AM
Sep-18-23 07:32PM
10:14AM
Sep-08-23 11:35AM
Sep-06-23 12:04PM
Aug-28-23 07:32PM
01:03PM
10:47AM
07:00AM
Aug-24-23 07:00AM
Aug-21-23 01:05PM
Aug-18-23 07:32PM
Aug-15-23 07:00AM
Aug-14-23 07:00AM
Aug-08-23 12:36PM
07:12AM
06:30AM
06:30AM
Aug-05-23 09:49AM
Jul-28-23 05:14PM
Jul-13-23 07:00AM
Jul-10-23 07:00AM
Jun-22-23 02:55PM
12:57PM
08:00AM
08:00AM
07:38AM
07:38AM
Jun-16-23 11:23AM
Jun-01-23 07:00AM
May-29-23 06:47AM
May-25-23 07:00AM
May-18-23 07:00AM
May-16-23 10:45AM
07:00AM
May-12-23 09:07AM
May-10-23 07:00AM
May-03-23 06:30AM
06:30AM
May-02-23 07:00AM
06:40AM
Apr-19-23 07:22PM
Apr-17-23 07:00AM
Apr-13-23 07:00AM
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Nusse Roeland Director Mar 07 '24 Sale 76.98 10,400 800,627 43,097 Mar 11 04:04 PM Hippel James CFO Dec 19 '23 Option Exercise 31.26 47,289 1,478,254 104,850 Dec 21 04:06 PM Nusse Roeland Director Aug 30 '23 Option Exercise 22.40 32,000 716,800 60,811 Sep 01 04:06 PM Nusse Roeland Director Aug 30 '23 Sale 80.32 8,939 717,959 51,872 Sep 01 04:06 PM Kelderman Kim Pres. Diagnostics & Genom Aug 24 '23 Option Exercise 47.60 2,100 99,960 21,225 Aug 28 04:19 PM Kummeth Charles R. Chief Executive Officer Aug 15 '23 Option Exercise 0.00 17,632 0 1,286,944 Aug 17 04:14 PM Kummeth Charles R. Chief Executive Officer Aug 05 '23 Option Exercise 0.00 51,516 0 1,310,282 Aug 08 05:31 PM Hippel James CFO Aug 05 '23 Option Exercise 0.00 12,876 0 63,896 Aug 08 05:29 PM Kelderman Kim Pres. Diagnostics & Genom Aug 05 '23 Option Exercise 0.00 8,060 0 23,264 Aug 08 05:28 PM Kummeth Charles R. Chief Executive Officer Jul 21 '23 Sale 88.36 80,000 7,069,024 1,258,766 Jul 25 05:27 PM Kummeth Charles R. Chief Executive Officer Jun 30 '23 Option Exercise 26.65 616,676 16,434,415 1,729,493 Jul 05 06:38 PM Kummeth Charles R. Chief Executive Officer Jun 07 '23 Sale 83.00 322 26,726 1,112,817 Jun 09 04:07 PM HIGGINS JOHN L Director Apr 28 '23 Option Exercise 21.85 16,000 349,600 39,360 May 02 04:49 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite